GeneDx is trading at $74.39 (+7.04%) after a Q2 revenue beat and analyst support.
- Q2 revenue reached $114.4 million, exceeding expectations; adjusted net income returned to $0.4 million.
- Record exome and genome testing volume totaled 30,785, up 32% year over year.
- Canaccord raised its price target to $90 from $75, maintaining a Buy rating. GAAP net loss was $17.7 million, amid reimbursement-rate concerns.